|
2NYY
Crystal structure of botulinum neurotoxin type A complexed with monoclonal antibody CR1
Deposited 2006-11-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
1–1295(1295 aa)
|
Not recorded
|
ZN ZINC ION × 1
CA CALCIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.5;297 K;8% PEG 20000, 8% PEG 550 MME, 200 mM calcium acetate, 100 mM sodium acetate, pH 5.50, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 2.61 Å
R-free 0.246
|
|
2NZ9
Crystal structure of botulinum neurotoxin type A complexed with monoclonal antibody AR2
Deposited 2006-11-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain A
1–1295(1295 aa)
|
Not recorded
|
ZN ZINC ION × 1
CA CALCIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.6;297 K;8% PEG 20000, 8% PEG 550 MME, 200 mM calcium acetate, 100 mM sodium acetate, pH 5.60, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 3.79 Å
R-free 0.278
|
|
2NZ9
Crystal structure of botulinum neurotoxin type A complexed with monoclonal antibody AR2
Deposited 2006-11-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 3
PDB declaration: trimeric
|
Chain B
1–1295(1295 aa)
|
Not recorded
|
ZN ZINC ION × 1
CA CALCIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.6;297 K;8% PEG 20000, 8% PEG 550 MME, 200 mM calcium acetate, 100 mM sodium acetate, pH 5.60, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 3.79 Å
R-free 0.278
|
|
2VU9
CRYSTAL STRUCTURE OF BOTULINUM NEUROTOXIN SEROTYPE A BINDING DOMAIN IN COMPLEX WITH GT1B
Deposited 2008-05-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
876–1296(421 aa)
Fragment:BINDING DOMAIN, RESIDUES 876-1296
|
Not recorded
|
MG MAGNESIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;21% PEG3350, 0.2 M MGCL2, 0.1 M BISTRIS PH5.5
|
Resolution 1.60 Å
R-free 0.186
|
|
2VUA
Crystal Structure of the Botulinum Neurotoxin Serotype A binding domain
Deposited 2008-05-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
876–1296(421 aa)
Fragment:BINDING DOMAIN, RESIDUES 876-1296
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.2;18% PEG3350, 0.2 M MGCL2, 0.1 M BISTRIS PH 5.2
|
Resolution 1.70 Å
R-free 0.205
|
|
3BTA
CRYSTAL STRUCTURE OF BOTULINUM NEUROTOXIN SEROTYPE A
Deposited 1998-08-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
1–1295(1295 aa)
Fragment:FULL LENGTH TOXIN
|
Not recorded
|
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7;pH 7.0
|
Resolution 3.20 Å
R-free 0.280
|
|
3FUO
The Crystal structure of receptor binding domain of botulinum neurotoxin serotype A
Deposited 2009-01-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
871–1296(426 aa)
Fragment:sequence database residues 871-1296
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.6;292 K;0.1 M Hepes pH 7.6, 12% PEG8K, 8% glycerol and 0.1 M NaCl, VAPOR DIFFUSION, HANGING DROP, temperature 292K
|
Resolution 1.80 Å
R-free 0.248
|
|
3ZUR
Crystal structure of an engineered botulinum neurotoxin type A- SNARE23 derivative, LC0-A-SNAP25-Hn-A
Deposited 2011-07-19
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
3–431(429 aa)
Fragment:CATALYTIC DOMAIN, RESIDUES 3-431, SNAP25, RESIDUES 145-206, TRANSLOCATION DOMAIN RESIDUES, 454-865
Chain A
454–865(412 aa)
Fragment:CATALYTIC DOMAIN, RESIDUES 3-431, SNAP25, RESIDUES 145-206, TRANSLOCATION DOMAIN RESIDUES, 454-865
|
Mutation:YES
Mutation:YES
|
SO4 SULFATE ION × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5;0.1 M TRIS PH 7.5, 0.2 M LISO4, 15% PEG 3350.
|
Resolution 2.71 Å
R-free 0.266
|
|
3ZUR
Crystal structure of an engineered botulinum neurotoxin type A- SNARE23 derivative, LC0-A-SNAP25-Hn-A
Deposited 2011-07-19
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
3–431(429 aa)
Fragment:CATALYTIC DOMAIN, RESIDUES 3-431, SNAP25, RESIDUES 145-206, TRANSLOCATION DOMAIN RESIDUES, 454-865
Chain B
454–865(412 aa)
Fragment:CATALYTIC DOMAIN, RESIDUES 3-431, SNAP25, RESIDUES 145-206, TRANSLOCATION DOMAIN RESIDUES, 454-865
|
Mutation:YES
Mutation:YES
|
SO4 SULFATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5;0.1 M TRIS PH 7.5, 0.2 M LISO4, 15% PEG 3350.
|
Resolution 2.71 Å
R-free 0.266
|
|
4EJ5
Crystal structure of the catalytic domain of botulinum neurotoxin BoNT/A wild-type
Deposited 2012-04-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
1–425(425 aa)
Fragment:UNP residues 1-425
|
Not recorded
|
ZN ZINC ION × 1
EDO 1,2-ETHANEDIOL × 3
SO4 SULFATE ION × 1
IMD IMIDAZOLE × 1
CO3 CARBONATE ION × 1
GOL GLYCEROL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6;293 K;8.3% monomethyl polyethylene glycol 2000, 0.17 M lithium sulfate, 6.25% 4,2 methyl pentane diol, 0.1 M imidazole malate, pH 6.0, cryoprotectant: 18% MPEG2K, 22% MPD, 10% DMSO, .050 M bicine, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293.0K
|
Resolution 1.87 Å
R-free 0.208
|
|
4EL4
Crystal structure of the catalytic domain of botulinum neurotoxin BoNT/A C134S/C165S double mutant
Deposited 2012-04-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
1–425(425 aa)
Fragment:UNP residues 1-425
|
Mutation:C134S, C165S
|
ZN ZINC ION × 1
GOL GLYCEROL × 2
IMD IMIDAZOLE × 2
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6;293 K;reservoir: 29% MPEG2K, 0.04 M Li2SO4, 0.1 M imidazole-HCl pH 6.0, cryoprotectant: 18% MPEG2K, 22% MPD, 10% DMSO, 0.050 M bicine, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 293.0K
|
Resolution 1.20 Å
R-free 0.202
|
|
4ELC
Crystal structure of the catalytic domain of botulinum neurotoxin BoNT/A C134 mutant with MTSEA modified Cys-165
Deposited 2012-04-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
1–425(425 aa)
Fragment:UNP residues 1-425
|
Mutation:C134S
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
ZN ZINC ION × 1
IMD IMIDAZOLE × 2
LMR (2S)-2-hydroxybutanedioic acid × 1
DMS DIMETHYL SULFOXIDE × 3
SO4 SULFATE ION × 2
MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 2
LI LITHIUM ION × 3
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.80 Å
R-free 0.223
|
|
4HEV
Clostridium Botulinum Serotype A Light Chain Inhibited By Adamantane Hydroxamate
Deposited 2012-10-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
1–425(425 aa)
Fragment:UNP Residues 1-425
|
Not recorded
|
ZN ZINC ION × 1
AXM N-hydroxy-2-[(3S,5S,7S)-tricyclo[3.3.1.1~3,7~]dec-1-yl]acetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;298 K;10-12mg/ml enzyme in 50mM NaPO4, 2mM EDTA, pH 6.5; and 10-15% polyethylene glycol (PEG) 2,000 monomethyl ester, 0.2-0.3M K2HPO4, 0.1M D,L-malic acid, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.50 Å
R-free 0.248
|
|
4HEV
Clostridium Botulinum Serotype A Light Chain Inhibited By Adamantane Hydroxamate
Deposited 2012-10-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
1–425(425 aa)
Fragment:UNP Residues 1-425
|
Not recorded
|
ZN ZINC ION × 1
AXM N-hydroxy-2-[(3S,5S,7S)-tricyclo[3.3.1.1~3,7~]dec-1-yl]acetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;298 K;10-12mg/ml enzyme in 50mM NaPO4, 2mM EDTA, pH 6.5; and 10-15% polyethylene glycol (PEG) 2,000 monomethyl ester, 0.2-0.3M K2HPO4, 0.1M D,L-malic acid, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.50 Å
R-free 0.248
|
|
4IQP
Crystal Structure of HCRA-W1266A
Deposited 2013-01-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
871–1296(426 aa)
|
Mutation:W1266A
|
GOL GLYCEROL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;pH 7.5;292 K;0.1 M Hepes, 12% PEG3350, 100 mM NaCl, pH 7.5, EVAPORATION, temperature 292K
|
Resolution 2.30 Å
R-free 0.246
|
|
4JRA
CRYSTAL STRUCTURE OF THE BOTULINUM NEUROTOXIN A RECEPTOR-BINDING DOMAIN IN COMPLEX WITH THE LUMINAL DOMAIN Of SV2C
Deposited 2013-03-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
871–1296(426 aa)
|
Not recorded
|
CL CHLORIDE ION × 6
NA SODIUM ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 7.5;293 K;100 mM Hepes pH 7.5, 6% PEG 8000, 8% Glycerol, 100 mM NaCl, VAPOR DIFFUSION, temperature 293K
|
Resolution 2.30 Å
R-free 0.269
|
|
4JRA
CRYSTAL STRUCTURE OF THE BOTULINUM NEUROTOXIN A RECEPTOR-BINDING DOMAIN IN COMPLEX WITH THE LUMINAL DOMAIN Of SV2C
Deposited 2013-03-21
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
871–1296(426 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 7.5;293 K;100 mM Hepes pH 7.5, 6% PEG 8000, 8% Glycerol, 100 mM NaCl, VAPOR DIFFUSION, temperature 293K
|
Resolution 2.30 Å
R-free 0.269
|
|
4ZJX
Crystal structure of the catalytic domain of botulinum neurotoxin serotype A with a Novel Cyclic Peptide Inhibitor
Deposited 2015-04-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
1–424(424 aa)
|
Not recorded
|
ZN ZINC ION × 1
SO4 SULFATE ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;293 K;25% PEG 3350, BIs-Tris and Lithium Sulfate
|
Resolution 1.94 Å
R-free 0.229
|
|
5JLV
Receptor binding domain of Botulinum neurotoxin A in complex with human glycosylated SV2C
Deposited 2016-04-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
872–1296(425 aa)
Fragment:UNP residues 872-1296
|
Mutation:T1158A
|
ACT ACETATE ION × 1
PO4 PHOSPHATE ION × 2
NAG 2-acetamido-2-deoxy-beta-D-glucopyranose × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;291 K;0.1 M sodium acetate pH 4.6, 20% PEG 3350, 0.2 M ammonium phosphate monobasic, 4% polypropylene glycol P 400
|
Resolution 2.00 Å
R-free 0.216
|
|
5JLV
Receptor binding domain of Botulinum neurotoxin A in complex with human glycosylated SV2C
Deposited 2016-04-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Other combination
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
872–1296(425 aa)
Fragment:UNP residues 872-1296
|
Mutation:T1158A
|
ACT ACETATE ION × 2
PO4 PHOSPHATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;291 K;0.1 M sodium acetate pH 4.6, 20% PEG 3350, 0.2 M ammonium phosphate monobasic, 4% polypropylene glycol P 400
|
Resolution 2.00 Å
R-free 0.216
|
|
5JMC
Receptor binding domain of Botulinum neurotoxin A in complex with rat SV2C
Deposited 2016-04-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
872–1296(425 aa)
Fragment:UNP residues 872-1296
|
Mutation:A1158T
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;100 mM sodium cacodylate, pH 6.5, 13% polyethylene glycol (PEG) 3350, 200 mM NaCl
|
Resolution 2.64 Å
R-free 0.275
|
|
5JMC
Receptor binding domain of Botulinum neurotoxin A in complex with rat SV2C
Deposited 2016-04-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain C
872–1296(425 aa)
Fragment:UNP residues 872-1296
|
Mutation:A1158T
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;100 mM sodium cacodylate, pH 6.5, 13% polyethylene glycol (PEG) 3350, 200 mM NaCl
|
Resolution 2.64 Å
R-free 0.275
|
|
5JMC
Receptor binding domain of Botulinum neurotoxin A in complex with rat SV2C
Deposited 2016-04-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain E
872–1296(425 aa)
Fragment:UNP residues 872-1296
|
Mutation:A1158T
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;100 mM sodium cacodylate, pH 6.5, 13% polyethylene glycol (PEG) 3350, 200 mM NaCl
|
Resolution 2.64 Å
R-free 0.275
|
|
5JMC
Receptor binding domain of Botulinum neurotoxin A in complex with rat SV2C
Deposited 2016-04-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain G
872–1296(425 aa)
Fragment:UNP residues 872-1296
|
Mutation:A1158T
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;100 mM sodium cacodylate, pH 6.5, 13% polyethylene glycol (PEG) 3350, 200 mM NaCl
|
Resolution 2.64 Å
R-free 0.275
|
|
5MK6
Crystal structure of the receptor-binding domain of botulinum neurotoxin A1 (crystal form 1)
Deposited 2016-12-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
871–1296(426 aa)
|
Not recorded
|
NA SODIUM ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 4;289.15 K;0.1 M MIB, 25% w/v PEG 1500
|
Resolution 1.45 Å
R-free 0.221
|
|
5MK7
Crystal structure of the receptor-binding domain of botulinum neurotoxin A1 (crystal form 2)
Deposited 2016-12-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
871–1296(426 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 4;289.15 K;0.1 M MIB, 25% w/v PEG 1500
|
Resolution 1.80 Å
R-free 0.223
|
|
5TPB
Binding domain of BoNT/A complexed with ganglioside variant
Deposited 2016-10-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
876–1296(421 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;293 K;20% PEG3350, 0.2 M potassium thiocyanate, 0.1 M BisTris propane pH 6.5
|
Resolution 2.60 Å
R-free 0.240
|
|
5TPB
Binding domain of BoNT/A complexed with ganglioside variant
Deposited 2016-10-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Other combination
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
876–1296(421 aa)
|
Not recorded
|
SIA N-acetyl-alpha-neuraminic acid × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;293 K;20% PEG3350, 0.2 M potassium thiocyanate, 0.1 M BisTris propane pH 6.5
|
Resolution 2.60 Å
R-free 0.240
|
|
5TPC
Binding domain of BoNT/A complexed with ganglioside
Deposited 2016-10-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
876–1296(421 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;20% PEG6000, 0.2 M MgCl2, 0.1 M Hepes pH 7.0
|
Resolution 2.00 Å
R-free 0.238
|
|
5V8P
Small Molecule Inhibitor ABS-143 Bound to the Botulinum Neurotoxin Serotype A Light Chain
Deposited 2017-03-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
1–424(424 aa)
Fragment:residues 1-424
|
Mutation:P2Q
|
ZN ZINC ION × 1
90G N-[3-(4-chlorophenyl)-1H-pyrazol-5-yl]-2-sulfanylacetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;298 K;Equal volumes of 10-12 mg/ml enzyme (50 mM Na2HPO4, 2 mM EDTA, pH 6.5) and crystallization buffer (10-15% polyethylene glycol [PEG] 2,000 monomethyl ester, 0.2-0.3 M K2HPO4, 0.1 M D,L-malic acid pH 7.0)
|
Resolution 2.50 Å
R-free 0.252
|
|
5V8P
Small Molecule Inhibitor ABS-143 Bound to the Botulinum Neurotoxin Serotype A Light Chain
Deposited 2017-03-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
1–424(424 aa)
Fragment:residues 1-424
|
Mutation:P2Q
|
ZN ZINC ION × 1
90G N-[3-(4-chlorophenyl)-1H-pyrazol-5-yl]-2-sulfanylacetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;298 K;Equal volumes of 10-12 mg/ml enzyme (50 mM Na2HPO4, 2 mM EDTA, pH 6.5) and crystallization buffer (10-15% polyethylene glycol [PEG] 2,000 monomethyl ester, 0.2-0.3 M K2HPO4, 0.1 M D,L-malic acid pH 7.0)
|
Resolution 2.50 Å
R-free 0.252
|
|
5V8R
Small Molecule Inhibitor ABS-143 Bound to the Botulinum Neurotoxin Serotype A Light Chain
Deposited 2017-03-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
1–424(424 aa)
Fragment:residues 1-424
|
Not recorded
|
ZN ZINC ION × 1
90J N-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]-2-sulfanylacetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 8.5;298 K;Mix equal volumes of 10 mg/ml enzyme (20 mM HEPES, pH 7.5, 50 mM NaCl) with crystallization solution (10%-15% polyethylene glycol monomethyl ether 2000, 0.3 M (NH4)2HPO4, 50 mM Tris, pH 8.5)
|
Resolution 1.90 Å
R-free 0.222
|
|
5V8R
Small Molecule Inhibitor ABS-143 Bound to the Botulinum Neurotoxin Serotype A Light Chain
Deposited 2017-03-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
1–424(424 aa)
Fragment:residues 1-424
|
Not recorded
|
ZN ZINC ION × 1
90J N-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]-2-sulfanylacetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 8.5;298 K;Mix equal volumes of 10 mg/ml enzyme (20 mM HEPES, pH 7.5, 50 mM NaCl) with crystallization solution (10%-15% polyethylene glycol monomethyl ether 2000, 0.3 M (NH4)2HPO4, 50 mM Tris, pH 8.5)
|
Resolution 1.90 Å
R-free 0.222
|
|
5V8U
Small Molecule Inhibitor ABS-143 Bound to the Botulinum Neurotoxin Serotype A Light Chain
Deposited 2017-03-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
1–424(424 aa)
Fragment:residues 1-424
|
Mutation:P2Q
|
ZN ZINC ION × 1
90M N-[3-(4-fluorophenyl)-4-methyl-1H-pyrazol-5-yl]-2-sulfanylacetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;298 K;Mix equal volumes of 10-12 mg/ml enzyme (50 mM Na2HPO4, 2 mM EDTA, pH 6.5) and crystallization buffer (10-15% polyethylene glycol [PEG] 2,000 monomethyl ester, 0.2-0.3 M K2HPO4, 0.1 M D,L-malic acid pH 7.0)
|
Resolution 2.05 Å
R-free 0.260
|
|
5V8U
Small Molecule Inhibitor ABS-143 Bound to the Botulinum Neurotoxin Serotype A Light Chain
Deposited 2017-03-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
1–424(424 aa)
Fragment:residues 1-424
|
Mutation:P2Q
|
ZN ZINC ION × 1
90M N-[3-(4-fluorophenyl)-4-methyl-1H-pyrazol-5-yl]-2-sulfanylacetamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;298 K;Mix equal volumes of 10-12 mg/ml enzyme (50 mM Na2HPO4, 2 mM EDTA, pH 6.5) and crystallization buffer (10-15% polyethylene glycol [PEG] 2,000 monomethyl ester, 0.2-0.3 M K2HPO4, 0.1 M D,L-malic acid pH 7.0)
|
Resolution 2.05 Å
R-free 0.260
|
|
5VGV
Structure of the C. botulinum neurotoxin serotype A with Cu bound
Deposited 2017-04-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
1–425(425 aa)
|
Not recorded
|
CU COPPER (II) ION × 2
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;290 K;PEG8000 6%, Calcium Acetate 0.1 M, Sodium Cacodylate 0.1 M
|
Resolution 2.60 Å
R-free 0.252
|
|
5VGX
Structure of the C. botulinum neurotoxin serotype A with Hg bound
Deposited 2017-04-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
1–425(425 aa)
|
Not recorded
|
HG MERCURY (II) ION × 1
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;290 K;PEG8000 8%, Calcium Acetate 0.2 M, Sodium Cacodylate 0.1 M
|
Resolution 2.15 Å
R-free 0.246
|
|
6DKK
Structure of BoNT
Deposited 2018-05-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
547–871(325 aa)
Chain B
547–871(325 aa)
|
Not recorded
|
PO4 PHOSPHATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.1;291 K;1.4 M sodium potassium phosphate and 0.1 M potassium sodium tartrate tetrahydrate
|
Resolution 2.70 Å
R-free 0.223
|